Yes, I follow everything that has to do with this disease and this company! :) (I have a sister who has had CFS/ME for 27 years and has taken ampligen twice.)
We can approach them, but we'd never get an answer back, that might be inside information. So, we must piece together what we can. I think there is a lot happening in the background. Consider:
Yesterday the NIH received an extra 2 billion. They now have the money to fulfill their promise of throwing significant bucks towards CFS/ME. I think they must include some kind of clinical trial form ampligen in their plans. See my Cort Johnson post below. The CDC working on a readily accessible test for NK cell function is big. There aren't many drugs that can improve NK cell function, ampligen is one and it has been through an FDA phase III. So, more patience required - rumor (and signs) has it that big bucks from several gov't agencies are coming for CFS - we'll know within couple of months I think. Peterson is at the center of all things ampligen and CFS - read as much as you can about him. And follow Cort Johnson who blogs for Peterson's Simmaron Research Group. HEB backed off on raising prices on ampligen until March 31. IMO, that's the window we are looking at.Ignore the games the predatory hedge fund is playing - hang on to your shares.
The other piece of good news - last week clinicaltrials.gov was updated for hemispherx's flu program. The phase II is fully enrolled. This has BARDA implications as we've got the best performing combo to date. BARDA requires an applicant to be at the phase II level and also be a sustainable company. Three sources for income next year. NIH clinical trial for amplegn, alferon manufacturing, and BARDA.
Market Data 
Markets 
AI
